Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017

Coccidioidomycosis skin testing appears to be uncommon, based on US health insurance claims data. Patient demographic features were consistent with the approval of the test for adults, but few patients had previous coccidioidomycosis diagnosis codes supporting its use for detecting delayed-type hype...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedict, Kaitlin, McCotter, Orion Z., Jackson, Brendan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045843/
https://www.ncbi.nlm.nih.gov/pubmed/32091378
http://dx.doi.org/10.3201/eid2603.190798
_version_ 1783501856086949888
author Benedict, Kaitlin
McCotter, Orion Z.
Jackson, Brendan R.
author_facet Benedict, Kaitlin
McCotter, Orion Z.
Jackson, Brendan R.
author_sort Benedict, Kaitlin
collection PubMed
description Coccidioidomycosis skin testing appears to be uncommon, based on US health insurance claims data. Patient demographic features were consistent with the approval of the test for adults, but few patients had previous coccidioidomycosis diagnosis codes supporting its use for detecting delayed-type hypersensitivity in those with a history of pulmonary coccidioidomycosis.
format Online
Article
Text
id pubmed-7045843
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-70458432020-03-07 Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017 Benedict, Kaitlin McCotter, Orion Z. Jackson, Brendan R. Emerg Infect Dis Research Letter Coccidioidomycosis skin testing appears to be uncommon, based on US health insurance claims data. Patient demographic features were consistent with the approval of the test for adults, but few patients had previous coccidioidomycosis diagnosis codes supporting its use for detecting delayed-type hypersensitivity in those with a history of pulmonary coccidioidomycosis. Centers for Disease Control and Prevention 2020-03 /pmc/articles/PMC7045843/ /pubmed/32091378 http://dx.doi.org/10.3201/eid2603.190798 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Benedict, Kaitlin
McCotter, Orion Z.
Jackson, Brendan R.
Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title_full Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title_fullStr Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title_full_unstemmed Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title_short Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–2017
title_sort coccidioidomycosis skin testing in a commercially insured population, united states, 2014–2017
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045843/
https://www.ncbi.nlm.nih.gov/pubmed/32091378
http://dx.doi.org/10.3201/eid2603.190798
work_keys_str_mv AT benedictkaitlin coccidioidomycosisskintestinginacommerciallyinsuredpopulationunitedstates20142017
AT mccotterorionz coccidioidomycosisskintestinginacommerciallyinsuredpopulationunitedstates20142017
AT jacksonbrendanr coccidioidomycosisskintestinginacommerciallyinsuredpopulationunitedstates20142017

Ejemplares similares